Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St futures muted as investors monitor US-Iran negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Leerink Partners Reiterates Outperform Rating on Repligen (RGEN)
March 4, 2025 9:50 AM ESTLeerink Partners analyst Puneet Souda reiterated an Outperform rating and $200.00 price target on Repligen (NASDAQ: RGEN)
The analyst comments "Bottom Line: This morning, RGEN (OP) announced the acquisition of MASS's (MP) bioprocessing desktop portfolio including REBEL, MAVERICK/MAVEN, and ZipChip (overall ~450 total... More
